LONDON, June 15, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Dobutamine Injection, USP, in a 250mg/20mL vial in the US. With this ...

Hikma is introducing dobutamine injection, in a 250 mg/20 ml vial. With this launch, Hikma’s growing U.S. portfolio of sterile injectable medicines now exceeds 150 products spanning a wide range of ...

Cardiogenic shock is associated with substantial morbidity and mortality. Although inotropic support is a mainstay of medical therapy for cardiogenic shock, little evidence exists to guide the ...

A head-to-head randomized comparison of milrinone and dobutamine — the most used inotropes in cardiogenic shock therapy in North America — failed to find a significant advantage for one agent over the ...